Introduction
Doxorubicin, an anthracycline, is one of the most widely used anticancer chemotherapeutic agents. It has strong antiproliferative effects on many solid tumors and it is currently used for the treatment of breast, ovarian, and lung cancers (Monneret, 2001) . Doxorubicin intercalates into DNA and causes double-stranded breaks by inhibiting topoisomerase II (Tewey et al., 1984) .
Despite its clinical efficacy, Doxorubicin suffers from drawbacks that are common of all chemotherapeutic agents: it is not tumor selective and therefore affects healthy tissue, causing severe side effects such as cardiotoxicity and myelosuppression (da Rocha et al., 2001) , and intrinsic or acquired resistance to the drug is developed by tumors (Moscow and Cowan, 1988) . For instance, the multidrug resistance-associated p-glycoprotein (p-gp) is a transmembrane pump that facilitates active cellular efflux of toxic compounds, thereby reducing cytotoxicity (Gottesman et al., 2002) .
Several approaches have been developed in order to deliver specifically Doxorubicin to tumor cells using monoclonal antibodies (mAbs) or small peptides as carrier molecules (Arap et al., 1998; Nagy et al., 1998; King et al., 1999; Stan et al., 1999; Garsky et al., 2001; Langer et al., 2001) . Targeted chemotherapy couples a drug to a carrier molecule (ligand), and depends on the ability of the ligand to bind selectively to the target tumor cells in such a way that it may increase the drug concentration near the tumor while decreasing systemic toxicity. Therefore, ligand selection is critical because the 'tumor marker' must be overexpressed selectively in the target. Most growth factor receptors were initially identified as oncogenes because of their ability to transform cells. As many different tumors overexpress type I insulin-like growth factor receptor (IGF-IR) (Adams et al., 2000) , and the receptor plays a central role in malignant transformation and growth (Baserga, 1999) , it is a validated target and is attractive for immunoconjugate therapy.
Ideally, the conjugate should be designed as a prodrug, which is stable and inactive in circulation but with the active form of the drug released in the target tumor tissue after internalization and cleavage of the prodrug conjugate. In a chemical conjugation strategy, diols in the antibody's carbohydrates can be reacted with the amine or hydrazide residues of drug forming a C-N linkage (Wolfe and Hage, 1995; Omelyanenko et al., 1996; Hage et al., 1997) . The C-N linkage has been shown to be relatively stable in circulation, while the drug was present inside tumor cells following internalization (Stan et al., 1999; Casares et al., 2001) .
One important issue is whether targeted chemotherapy can also help to bypass p-gp-mediated drug resistance, but this has never been tested in vivo.
Here, we report the design, synthesis, and evaluation of a targeted cytotoxic conjugate containing Doxorubicin as the effector molecule and a mAb directed to IGF-IR as the targeting delivery agent. The conjugate was more active ex vivo and in vivo than free Doxorubicin or free Doxorubicin plus free mAb. The conjugate was highly selective and specific towards cells expressing IGF-IR. More importantly, the conjugate allowed bypassing of the p-gp-mediated resistance ex vivo, and in vivo without any evidence of systemic toxicity. These findings have great importance since multidrug resistance is a major cause of treatment failure, and may lead to an improvement of anticancer agents.
Results

Binding of Doxorubicin-conjugated antibodies
FACScan binding assays (Guillemard and Saragovi, 2001 ) comparing free mAb a-IR3 with Doxorubicinconjugated a-IR3 mAb demonstrated that the chemistry used for coupling did not affect mAb receptor binding and saturability profiles (data not shown). This result indicates that coupling antibodies through carbohydrates moieties largely present in the F c domain (distant from the antigen binding site) prevents loss of antibody binding.
Target specificity and ex vivo/in vivo efficacy of Doxorubicin-a-IR3 conjugates
The conjugate was cytotoxic for NIH-IGF-IR þ but was inactive towards wild-type NIH-3T3 cells, indicating selectivity. In contrast, free Doxorubicin was nonselective and cytotoxic towards both cell lines (Figure 1a) . Further, we demonstrated the specificity of the conjugate in ligand competition assays. Killing by the conjugate was abolished by blocking the receptor target with 10 molar excess free mAb a-IR3, but not with control mouse IgG (data not shown; see Guillemard and Saragovi, 2001) . In additional controls, free Doxorubicin had the same cytotoxicity towards both cell lines whether or not we added mouse IgG or mAb a-IR3.
Free Doxorubicin and the conjugate had equivalent cytotoxicity at equimolar concentrations tested in cell culture, but the conjugate had higher selectivity. These ex vivo assays were performed by culture with drugs for 72 h. Interestingly, at shorter incubation times (e.g. 24 h) the conjugate was highly effective, whereas free Doxorubicin was not (data not shown; for similar results with other conjugates, see Guillemard and Saragovi, 2001) , suggesting different time-dependent kinetics wherein the conjugate is more efficient than Doxorubicin either or both at internalization/intracellular accumulation. Note that the overall efficacy of the cytotoxicity ex vivo reaches a plateau and does not improve at high drug concentrations. This plateau is typical for a drug like Doxorubicin or Taxol that kills in a cell cycle dependent manner or that requires entry in a specific phase of the cell cycle (Schiff et al., 1979; Schiff and Horwitz, 1980; Tannock and Hill, 1992; Guillemard and Saragovi, 2001) . Next, we evaluated the in vivo antitumor efficacy of the conjugate versus Doxorubicin using NIH-IGF-IR þ cells implanted in nude mice (see in vivo treatment flow chart in Figure 1b) . The growth of preimplanted tumors was measured 10 days after the initiation of drug treatment (day 0 in the graph). Conjugate treatment (0.4 mg doses) affords a significantly lower tumor load (Pp0.05) than saline control at all days measured. In contrast, Doxorubicin (80 mg doses) was significantly different from saline control only at days 1-10 ( Figure 1c) . From day 11 onwards, tumor volume was significantly smaller in the conjugate-treated mice, even compared to Doxorubicin treatment.
These data would suggest enhanced in vivo efficacy by the conjugate, and an improved therapeutic index of 200-fold. In addition, because the effective doses of free Doxorubicin are quite toxic to the mice, we deem the overall therapeutic index of the conjugate to be higher than 200-fold (also see Figure 3 below).
Enhanced killing by conjugates versus Doxorubicin at low drug doses
We tested a range of drug doses in culture using the human nasopharyngeal tumor KB cells and the derivative drug-resistant KB-V cells (Figure 2a ). Both cell lines express equal levels of IGF-IR (B60 000 receptors/cell, data not shown), but the KB-V cells express high levels of p-gp and are quite resistant to Doxorubicin killing.
In KB cells, low dose conjugate (5-50 nM) killed significantly better than Doxorubicin (Pp0.05). Higher concentrations of drugs killed with similar efficacy. In the drug-resistant KB-V cells, only the conjugate afforded significant killing, while even the highest Doxorubicin concentration tested (320 nM) did not reach the IC 50 . Note that, as with the NIH3T3 cells, the overall efficacy of the cytotoxicity ex vivo reaches a plateau at high drug concentrations. From several similar assays, we determined the ex vivo IC 50 for these drugs.
The conjugate had an IC 50 of B30 nM for both KB and the drug-resistant KB-V cells; while Doxorubicin had an IC 50 B60 nM KB cells, and the IC 50 was not Bypassing MDR resistance by targeting cell surface tumor markers V Guillemard and H Uri Saragovi detectable for KB-V cells (Figure 2b ). To evaluate further bypassing of p-gp resistance, we determined the IC 50 for conjugate and free Doxorubicin in the presence or absence of the p-gp inhibitor Verapamil (Figure 2b ). Verapamil did not alter the IC 50 of the conjugates towards either cell line. In contrast, Verapamil allowed the detection of free Doxorubicin IC 50 B150 nM towards the drug-resistant KB-V cells, but as expected did not alter the cytotoxicity towards the KB cells. Controls with a combination of Doxorubicin and free mAb did not affect the IC 50 , indicating again that in these assays the mAb is a carrier, and if it has any intrinsic pharmacological effect it is not additive with that of Doxorubicin.
We confirmed these results using a complementary test, the soft agar colony formation assay (Figure 2c) . In KB cells, 20 nM Doxorubicin reduced foci formation by 30% but did not affect foci in KB-V cells. In contrast, 20 nM conjugate reduced foci formation in both cell lines by B60%. As shown earlier in the MTT assays, low doses of the conjugate were more potent than low doses of free Doxorubicin (6 nM conjugate versus 20 nM drugs). Moreover, the conjugate killed both cell types with similar efficacy regardless of p-gp expression.
Bypassing drug resistance in vivo
To test whether the conjugate can bypass p-gp resistance in vivo, we implanted mice with KB or KB-V cells and treated them with drugs ( Figure 3 ) (using the same experimental protocol described in Figure 1b ). Mice bearing visible preimplanted tumors were administered five injections with drugs or controls (days À10, À8, À6, À4, and À2), and tumor lead was measured from day 0 onwards.
The treatment of drug-sensitive KB tumors with either Doxorubicin 80 mg/dose or conjugate 0.4 mg/dose (a 200-fold difference in dosage) led to a significant reduction in tumor load. A statistical comparison showed that in the drug-sensitive KB cells, Doxorubicin affords better results than conjugate from day 10 onward (Pp0.05). However, all animals treated with effective Doxorubicin doses died by day 16 (Figure 3) .
The treatment of drug-resistant KB-V tumors with Doxorubicin or conjugate at 200-fold different concentrations also achieved a significant reduction in tumor volume. However, in this case, tumor reduction was comparable for both drugs, indicating that free Doxorubicin was less effective because of drug resistance, whereas the conjugate was relatively unaffected in vivo by p-gp expression in the tumor. Moreover, as reported for KB tumor-bearing mice, all animals treated with effective Doxorubicin doses died by day 14 (Figure 3) .
The deaths caused by treatment with effective doses of Doxorubicin were due to drug toxicity and wasting, and the mice had red/transparent skin. In contrast, the conjugate (0.4 mg/dose) reduced both KB and KB-V tumor load to a statistically significant level from day 10 onwards (Pp0.05), indicating that it can bypass p-gp resistance in vivo without toxicity.
Systemic toxicity is caused by Doxorubicin but not by the conjugate
We studied blood samples to evaluate bone marrow toxicity and body weight as an indicator of systemic toxicity (Table 1) . Mice treated with 80 mg doses of Doxorubicin suffered from abnormal hematological values including hematocrit, hemoglobin, red blood cells (RBCs), lymphocytes, and monocytes. These mice also suffered weight loss. In contrast, mice treated with conjugate at effective doses (0.4 mg/dose) did not suffer hematological abnormalities or weight loss (Table 1) .
Comparison of conjugate versus Doxorubicin efficacy in vivo
While conjugate and Doxorubicin are equally effective ex vivo, the data (Figures 2 and 3) showed that in vivo the conjugate is a more effective agent. From these encouraging data, it seemed logical to optimize a drug delivery schedule aiming to reduce dose and frequency. It was also of particular interest to compare this versus a schedule for Doxorubicin that was effective without toxicity. Moreover, we also aimed to determine whether Figure 3 Conjugates bypass p-gp-mediated resistance in vivo with reduced toxicity. Tumor size of mice bearing KB or KB-V tumors. Treatment and measurement protocols are as in Figure 1b . All points have7s.e.m. bars, except days 10-14 Doxorubicin treatments. This treatment was highly toxic and all animals died between days 8 and 16; hence the n value did not allow statistical analyses Bypassing MDR resistance by targeting cell surface tumor markers V Guillemard and H Uri Saragovi therapy could be achieved in a mouse model of chemotherapy where tumor burden is larger before drug injection (Figure 4 ). Nude mice were implanted subcutaneously with drugresistant KB-V cells; the tumors were allowed to grow to an average B30 mm 3 . Mice bearing tumors were randomized (n ¼ 6 per group) and injected a total of three times, once weekly (injections at days 0, 8, and 15), with drugs or controls. Tumor volume was measured from day 0 onwards (Figure 4 ).
In this model, conjugate (0.4 mg/dose) was significantly better than saline from days 6 to 23 of the assay. In contrast, Doxorubicin (80 mg/dose) was better than saline only from days 17 to 23 of the assay. However, there was no significant toxicity or weight loss in the Doxorubicin group, but the mice had a slight red coloration. Owing to Animal Welfare concerns pertaining to tumor load, four of the six mice in the saline group were euthanized on day 19; hence the saline graph terminates on that date. Also, four of the six mice in the Doxorubicin (80 mg/dose) group were euthanized on day 23. For the conjugate (0.4 mg/dose) group, two of the six mice survived past day 60 (or longer had we not euthanized them), and they had small necrotic tumors of volumes less than 200 mm 3 . While this observation seems compelling, it is not shown because the n values do not permit statistical analyses.
Enhanced intracellular accumulation of conjugate
Intracellular drug accumulation was studied in NIH-IGF-IR cells, in FACScan studies focused on Doxorubicin. Cells were exposed to various concentrations of either conjugate or free Doxorubicin (1 h 371C), and then were washed extensively to remove excess drug and material bound at the extracellular milieu. The intracellular Doxorubicin was then measured by FACScan. Drug delivery through conjugate was efficient, and low concentrations of conjugate afford improved intracellular accumulation relative to free Doxorubicin ( Figure 5 ).
Enhanced intracellular retention of conjugate
Similar FACScan assays were performed using KB (doxorubicin sensitive) and KB-V (doxorubicin resistant, expressing p-gp) cells to study the impact of p-gp overexpression in drug accumulation. In these assays, after removal of material bound at the extracellular milieu, a 'washout' step was introduced, where cells were incubated again for 1 h at 371C to allow drug efflux, or at 41C as control for diffusion ( Figure 6 ).
Initial conjugate and free Doxorubicin concentrations were adjusted so that they would result in similar intracellular drug accumulation before the washout step. Average blood cell counts of nude mice bearing KB tumors, 2 days after the last drug treatment (n ¼ 2). Average weight (n ¼ 4) of mice 11 days after the last drug treatment. Treatments shown are only those that had in vivo efficacy at reducing tumor load compared to saline . Three injections, once weekly (at days 0, 8, and 15) were given, and tumor measurements were started at day 0 Figure 5 Efficient intracellular drug accumulation by conjugate delivery. NIH-IGF-IR cells were exposed to various concentrations of drugs to allow diffusion or internalization, then excess drug and drug bound extracellularly was washed off. Intracellular Doxorubicin was immediately measured by FACScan. For clarity, only some concentrations are shown. Representative of two independent assays Bypassing MDR resistance by targeting cell surface tumor markers V Guillemard and H Uri Saragovi As seen before in NIH-IGF-IR cells, the conjugate had improved intracellular accumulation relative to free Doxorubicin.
In KB cells, Doxorubicin delivered through either the conjugate or as free Doxorubicin was retained after the 1 h washout step (Figure 6a ). These data suggest that in these cells drug efflux or outward diffusion was very limited.
In contrast, in KB-V cells (p-gp þ ), only the Doxorubicin delivered through conjugate was retained efficiently, whereas drug delivered as free Doxorubicin was completely washed out (Figure 6b ). These data suggest that drug delivered through conjugate is not a good substrate for p-gp, or is not accessible to p-gp.
Discussion
IGF-I receptors are overexpressed in a variety of human tumors and are therefore choice targets for site-directed delivery of chemotherapeutics (Baserga, 1999; Adams et al., 2000) . We report the design and conjugation of an antibody targeting IGF-I receptors with the chemotherapeutic Doxorubicin, to deliver Doxorubicin efficiently and specifically to the tumor cells. This approach seems to overcome the major problems related to Doxorubicin treatment in vivo: systemic toxicity and p-gp-mediated resistance.
While targeted drug delivery has been used previously to enhance the therapeutic index of chemotoxic drugs in vivo (Guillemard and Saragovi, 2001), whether or not targeted drug delivery can bypass pgp resistance in vivo has never been published. With respect to in vitro data on pgp resistance, both positive and negative data have been reported (Fritzer et al., 1996; Munns et al., 1998; Matsui et al., 2002) . The present report is the first direct demonstration of efficient bypassing of pgp in vivo using a targeted chemotherapeutic.
Criteria for conjugation
We designed the conjugate to obtain a prodrug, inactive in circulation while fully active at the target. The chemical strategy used for coupling allowed the conjugate to retain desirable characteristics for the mAb (high selectivity, high affinity, internalization) and for the cytotoxic moiety (high toxicity after release of the drug inside the cell). Doxorubicin was linked via the amino group located in its sugar portion. This leads to Doxorubicin inactivation, since this position is crucial for its activity (Nagy et al., 1998) . Moreover, conjugated Doxorubicin linked to a hydrophilic carrier cannot diffuse freely through plasma membranes. Thus, the conjugate is a prodrug.
In the present study, we did not detect intrinsic cytotoxic activity by mAb a-IR3 that could add to the cytotoxicity of free Doxorubicin. However, others have noted that mAb a-IR3 is a competitive antagonist of the natural ligand of the target receptor IGF-1 (Hailey et al., 2002) , and can inhibit the in vitro growth of MCF7 cells; therefore we cannot rule out completely that the carrier mAb is inert. Nevertheless, the data show that in its free state (unconjugated) the mAb does not alter the efficacy of Doxorubicin in vitro and in vivo, and this is supported by the fact that conjugates are efficacious even at low concentration and frequency.
Improved potency, efficacy, and selectivity of conjugates Ex vivo, the cytotoxic potency of the conjugate was significantly better at cytotoxicity and inhibition of foci formation than free Doxorubicin or Doxorubicin plus free mAb, especially at low doses. This may be due to efficient 'transport' of the conjugate. Active transport can achieve cytotoxic concentrations inside the cell even at low drug doses because it is receptor mediated, while free Doxorubicin simply diffuses into cells and cannot achieve cytotoxic concentrations inside the cell at low drug doses.
Ex vivo, the efficacy of conjugate and free Doxorubicin was comparable; both agents killed cells to a similar degree after 3 days of drug exposure. However, the time kinetics of cytotoxicity differed and the conjugate killed cells significantly faster (data not shown). We reported this observation previously for mAb-paclitaxel conjugates (Guillemard and Saragovi, 2001 ). The cytotoxicity of Doxorubicin-mAb conjugate is dependent on the expression and availability of the target IGF-I receptor. We did not observe binding of the conjugate to cells that do not express the target receptors, and we did not observe cell death in cells that do express the target but where binding to the said target was blocked.
As expected, cells that express high receptor density (NIH-IGF-IR) are killed more efficiently than cells expressing low receptor density (KB or KB-V cells), because the amount of cytotoxic drug delivered is directly correlated to the number of mAbs binding to and internalizing in the target cell. Nevertheless, in vivo the conjugate exhibited dose-dependent cytotoxicity, and enhanced potency, and efficacy over Doxorubicin. Approximately 200-fold higher doses of Doxorubicin were required to achieve the same arrest of tumor growth as the conjugate.
Conjugation reduces systemic toxicity
The main toxicity caused by Doxorubicin is myelosuppresion. Indeed, all mice treated with effective Doxorubicin doses (Figure 3 ) died at B15 days post-treatment due to severe toxicity.
Adjusting the therapy schedule to optimal Doxorubicin conditions (Trail et al., 1993; Arap et al., 1998) did reduce systemic toxicity but also compromised the antitumor efficacy of Doxorubicin in vivo (Figure 4) . With the 'Doxorubicin-optimized' regimen, Doxorubicin (80 mg) was less efficacious than the conjugate (0.4 mg). In contrast, effective conjugate doses were not toxic under any schedule, and required 200-fold lower doses and lower frequency.
Since Doxorubicin therapy carries a high toxic cost and has a narrow therapeutic window, the improved therapeutic index of the conjugate may be deemed to be higher than 200-fold versus Doxorubicin.
Bypassing p-gp-mediated resistance
Multidrug resistance is a major cause of treatment failure, but the conjugate was effective at killing multidrug-resistant cells ex vivo and in vivo. Bypassing of p-gp-mediated resistance by the conjugate may be explained by three hypothetical mechanisms (Figure 7) .
The first mechanism is documented and pertains to efficient drug accumulation. Conjugate delivery can achieve concentrations that could saturate p-gpmediated resistance. We (Figures 5) and others (Stan et al., 1999; Casares et al., 2001 ) have demonstrated high drug accumulation after receptor-dependent internalization, approximately 20-fold better than free diffusion. However, it is important to note that in our opinion, these drug accumulation studies are dynamic and therefore are qualitative but not quantitative. In our experience, quantification requires applying a minimum of B0.5 mM free Doxorubicin or Doxorubicin-equivalent conjugate to the cells, whereas in the ex vivo and in vivo assays we are applying nM concentrations.
The second mechanism pertains to topological sequestration. As receptor-mediated internalization delivers Doxorubicin directly to the lysosomes, deep inside the cells and farther from the p-gp pump localized at the cell membrane, it is less available for excretion.
The third mechanism is reduced substrate recognition. The free amino group in the sugar moiety of Doxorubicin is a preferred substrate for p-gp (Salerno et al., 2002) . As this site is modified during conjugation to the mAb, the chemotherapeutic in the conjugate is perhaps not easily captured by p-gp.
With respect to the second and third hypothetical mechanisms above, we showed that intracellular drug delivered by conjugates is not rapidly removed by p-gp, whereas almost all of free Doxorubicin is removed within 1 h (Figure 6 ).
Conclusions
Site-directed delivery of Doxorubicin allowed potent, selective, specific, and efficient toxicity to multidrugresistant target tumor cells in vivo, with no systemic toxicity. This work is further proof that drug targeting is a valuable way to treat cancer and perhaps other pathologies. The characteristics of the conjugate make it a superior therapeutic compared to Doxorubicin.
Other mAbs or receptor-selective ligands, particularly to targets defined as oncogenic 'tumor markers', can be exploited using this technique. The clinically tried mAb Herceptin Shawver et al., 2002) , which targets HER2 receptors, would be a very Figure 7 Hypothetical model of internalized conjugates. In this work, we have shown enhanced target cell accumulation of conjugate versus free Doxorubicin. Release of free Doxorubicin drug from the conjugate has been shown previously (Stan et al., 1999; Casares et al., 2001) and occurs inside lysosomes. After entry into cell, only one pathway is possible for the conjugate. In contrast, Doxorubicin has three pathways: the drug diffuses outside the cell, it is pumped out by MDR from cell, or it is active inside the cell Bypassing MDR resistance by targeting cell surface tumor markers V Guillemard and H Uri Saragovi interesting carrier in our system because the ligand also has its own cytotoxic property that could add or synergize with that of the conjugated drug. Indeed, we have generated a highly potent conjugate of an HER2 ligand (Berezov et al., 2001 (Berezov et al., , 2002 coupled to Taxol (Guillemard et al., submitted) .
Pharmacokinetic and pharmacodynamic studies are in progress to further evaluate chemotoxic conjugates as drugs. The next logical step would be to synthesize conjugates comprising a drug and a smaller peptidic or nonpeptidic ligand to improve further the drug-like properties of these conjugates.
Materials and methods
Monoclonal antibodies
MAb a-IR3 is a mouse anti-human IGF-IR antibody (Kato et al., 1993) . It was purified and characterized as described (Maliartchouk and Saragovi, 1997) .
Synthesis of Doxorubicin-mAB a-IR3 conjugate
We derivatized MAb a-IR3 (100 mg) with 10 mM sodium periodate in 0.1 M acetate buffer pH 5.5 for 30 min (Omelyanenko et al., 1996) , leading to the formation of reactive aldehyde groups. We removed byproducts by size exclusion and exchanged the buffer to 1 M carbonate/bicarbonate buffer, pH 9.0. We added Doxorubicin (2 mg) for 16 h at 41C to form a Doxorubicin-mAb conjugate via the formation of Schiff's bases between reactive aldehydes of the mAb and amino group of the drug. We then reduced the conjugate (50 mM pyridine borane, 24 h at 41C) to stabilize the Schiff's bases, leading to the formation of a C-N linkage between the mAb and the drug (Stan et al., 1999) . We finally dialysed the conjugate against PBS. We quantified mAb-bound Doxorubicin using spectroscopy at 495 nm, using known concentrations of Doxorubicin as standard control, and measured a 1 : 2 molar ratio of mAb to bound Doxorubicin, meaning that on average two Doxorubicin coupled to one mAb.
Cell lines
NIH 3T3 cells are mouse fibroblasts that do not express IGF-IR. The NIH-IGF-IR þ cells are NIH 3T3 stably transfected with human IGF-IR cDNA (Kato et al., 1993) . KB cells are a human nasopharyngeal cancer cell line that overexpress IGF-IR, and KB-V cells are drug-resistant cells that overexpress p-gp (Fakata et al., 1998) .
Ex vivo cytotoxicity of the Doxorubicin-mAb a-IR3 conjugate We measured cytotoxicity using two assays. First, we measured survival/growth using the MTT assay in 96-well plates with cells plated7drugs or controls for 72 h (mAb a-IR3, conjugate, free Doxorubicin plus free mAb a-IR3) in the presence or absence of 6 mM Verapamil, a p-gp inhibitor (Tan et al., 2000) . In specificity controls, we competed the cytotoxicity of the conjugate by blocking its binding to target receptors with a 10-fold molar excess of unconjugated mAb a-IR3. Second, we measured the anchor-independent growth of the cells in soft agar colony assays (Screaton et al., 1997) in the absence or presence of Doxorubicin or the conjugate at equimolar Doxorubicin doses added to the top layer. We counted foci after 2 weeks.
In vivo tumor studies
We compared the in vivo efficacy of conjugate versus free Doxorubicin, or versus free Doxorubicin plus free mAb. The end point was arrest of tumor progression, and in the ability to kill p-gp-expressing cells that are resistant to Doxorubicin. We injected nude mice (6-8 weeks old, female) with single-cell suspensions of NIH-IGF-IR þ (10 5 cells/mouse), KB, or KB-V (8 Â 10 5 cells/mouse) subcutaneously in the left flank near the rib cage. We monitored tumor growth daily. After the volume of the tumors had reached B2 mm 3 , we randomized the mice and initiated treatments in five groups (n ¼ 5 in each group). Mice received a total of five injections every 2 days (for a total of 10 days). We gave all injections intraperitoneally on the right side to prevent direct contact of the agents with the subcutaneous tumor, and to assure that systemic circulation of the drugs had to be achieved (Guillemard and Saragovi, 2001) . Two doses of free Doxorubicin were compared with lower doses of conjugate. Free Doxorubicin was tested at 80 mg/ injection (equivalent to 20% of the LD 50 for these mice (data not shown)), and at 0.4 mg/injection. Conjugate treatment was tested at 0.4 and at 0.04 mg Doxorubicin-equimolar equivalent/ injection. Controls included saline, and free Doxorubicin injected together with nonconjugated aIR3 antibody. We measured tumor volumes every 2 days after completion of drug treatment for another B20 days, or earlier in the case of free Doxorubicin because animals suffered high morbidity/ mortality due to drug toxicity and had to be killed. McGill University IACUC approved all protocols.
Evaluation of systemic toxicity
We sampled blood 2 days after the last drug injection. Hematological values (measured by the Diagnostic and Research Support Service, McGill University Animal Resources Center) are used as surrogate markers of bone marrow and systemic toxicity. Data are shown as an average of the hematological values for two mice per group. We measured body and tumor weights for all mice at the experimental end point, and took representative pictures of the mice.
In vivo comparison of Doxorubicin and conjugate
We compared the in vivo efficacy of conjugate versus free Doxorubicin in a mouse model of chemotherapy where tumor burden is larger before drug injection. Nude mice were injected subcutaneously in the left flank near the rib cage with drugresistant KB-V cells, and the tumors were allowed to grow to an average B30 mm 3 . Mice bearing tumors were randomized (n ¼ 6 per group) and injected intraperitoneally in the right flank a total of three times, once weekly (at days 0, 8, and 15), with drugs or saline vehicle. Tumor volume was measured starting at day 0.
Comparison of intracellular accumulation and retention for conjugate versus free Doxorubicin Intracellular drug accumulation was studied in FACScan assays of NIH-IGF-IR cells, using the color of Doxorubicin. Cells were exposed to various concentrations of either conjugate or free Doxorubicin (1 h, 371C), and then were washed extensively at 41C (including a pH 4.5 citric acid wash) to remove excess drug and material bound at the extracellular milieu. For clarity, only some of the concentrations are shown. To study the impact of p-gp overexpression in drug accumulation, similar FACScan assays were carried out using KB (doxorubicin sensitive) and KB-V (doxorubicin resistant, expressing p-gp) cells. After removal of excess drug and material bound at the extracellular milieu, a 'washout' step was introduced where cells were incubated again for 1 h at 371C to allow drug efflux, or were incubated at 41C as control for diffusion.
Statistical analysis
We determined statistical significance using SYSTAT 7.0 software by ANOVA and the student's t-test with Bonferroni corrections. A P-value is significant when p0.05.
